



11-25-02

RECEIVED

NOV 27 2002

1614  
S  
✓

TECH CENTER 1600/2900

Patent

Attorney's Docket No. 002010-676

## EXPRESS MAIL:

"Express Mail" mailing label No. EL 863873752 US  
Date of Deposit November 22, 2002

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of )  
Konradi, et al. ) Group Art Unit: 1614  
Application No.: 09/910,466 ) Examiner: Not yet assigned  
Filed: July 19, 2001 ) Confirmation No.: 1745  
For: 3-(HETEROARYL) ALANINE )  
DERIVATIVES-INHIBITORS OF )  
LEUKOCYTE ADHESION )  
MEDIATED BY VLA-4 )

AMENDMENT/REPLY TRANSMITTAL LETTER

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Enclosed is a reply for the above-identified patent application.

- [ ] A Petition for Extension of Time is also enclosed.
- [ ] A Terminal Disclaimer and a check for [ ] \$55.00 (2814) [ ] \$110.00 (1814) to cover the requisite Government fee are also enclosed.
- [ ] Also enclosed is \_\_\_\_\_.
- [ ] Small entity status is hereby claimed.
- [ ] Applicant(s) request continued examination under 37 C.F.R. § 1.114 and enclose the [ ] \$370.00 (2801) [ ] \$740.00 (1801) fee due under 37 C.F.R. § 1.17(e).
- [ ] Applicant(s) previously submitted \_\_\_, on \_\_\_, for which continued examination is requested.
- [ ] Applicant(s) request suspension of action by the Office until at least \_\_\_, which does not exceed three months from the filing of this RCE, in accordance with 37 C.F.R. § 1.103(c). The required fee under 37 C.F.R. § 1.17(i) is enclosed.

[ ] A Request for Entry and Consideration of Submission under 37 C.F.R. § 1.129(a) (146/246) is also enclosed.

[ ] No additional claim fee is required.

NOV 27 2002

[X] An additional claim fee is required, and is calculated as shown below:

TECH CENTER 1600/2900

AMENDED CLAIMS					
	NO. OF CLAIMS	HIGHEST NO. OF CLAIMS PREVIOUSLY PAID FOR	EXTRA CLAIMS	RATE	ADDT'L FEE
Total Claims	85	MINUS = 30	55	× \$18.00 (1202) =	990.00
Independent Claims	2	MINUS 3 =	0	× \$84.00 (1201) =	0
If Amendment adds multiple dependent claims, add \$280.00 (1203)					
Total Amendment Fee					
If small entity status is claimed, subtract 50% of Total Amendment Fee					
<b>TOTAL ADDITIONAL FEE DUE FOR THIS AMENDMENT</b>					<b>\$990.00</b>


[X] A claim fee in the amount of \$ 990.00 is enclosed.

[ ] Charge \$ \_\_\_\_\_ to Deposit Account No. 02-4800.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17, 1.20(d) and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: November 22, 2002  
By:   
Julie L. Heinrich  
Registration No. 48 070

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(650) 622-2300



#610  
3114103  
83W

**EXPRESS MAIL:**

"Express Mail" mailing label No. EL 863873752 US  
Date of Deposit November 22, 2002

Patent  
Attorney's Docket No. 002010-676

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of )

ANDREI W. KONRADI, et al. )

Application No.: 09/910,466 )

Filed: July 19, 2001 )

For: 3-(HETEROARYL) ALANINE )  
DERIVATIVES-INHIBITORS OF )  
LEUKOCYTE ADHESION )  
MEDIATED BY VLA-4 )

) Group Art Unit: 1614

) Examiner: Unassigned

) Confirmation No.: 1745

**RECEIVED**  
NOV 27 2002  
TECH CENTER 1600/2900

**PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Before examination of the present application, please amend the specification and claims as follows.

**IN THE SPECIFICATION**

Please replace Table 1, on page 17 to 19 with the following table:

Cpd #	A	HetAr
1	[2-N(CH <sub>3</sub> ) <sub>2</sub> -5-CF <sub>3</sub> CH <sub>2</sub> ]pyrimidin-4-yl	2-(2,6-di-MeOPh)pyridin-5-yl
2	[2-N(CH <sub>3</sub> ) <sub>2</sub> -5-CF <sub>3</sub> CH <sub>2</sub> ]pyrimidin-4-yl	5-(2,6-di-MeOPh)pyridin-2-yl
3	[2-N(CH <sub>3</sub> ) <sub>2</sub> -5-CF <sub>3</sub> CH <sub>2</sub> ]pyrimidin-4-yl	3-(2,6-di-MeOPh)pyridazin-6-yl
4	[2-N(CH <sub>3</sub> ) <sub>2</sub> -5-CF <sub>3</sub> CH <sub>2</sub> ]pyrimidin-4-yl	5-(2,6-di-MeOPh)pyrimidin-2-yl